This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Top Investor Avoids Energy, Buys Microsoft

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Abbott Laboratories (ABT - Get Report)

Company Profile: Abbott Labs is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products.

1-Year Total Return: -12%

Schoenstein's Take: In whittling down the list of possible investment ideas, Schoenstein says the Jensen Portfolio looks for companies with recurring revenue streams -- something that protects against real downturns -- as well as something in the business that gives a company an advantage over their competition, assuming they're investing in those advantages that they've created. In the healthcare space, which represents 21.4% of the portfolio, that is found in patent protection.

Abbott Labs, at a portfolio weighting of 4.3%, isn't the largest health-care position the portfolio has but it has the most attractive characteristics. As they pertain to Abbott, there are competitive barriers to entry in the pharmaceutical space, plus patent protection in the device space, Schoenstein says.

"They've got good device products, like stents, which have been quite well received," he says. "But you also have nutritionals, which has a strong platform here in the U.S. that they are taking to emerging markets. There is also the idea that pharmaceuticals have to be the branded, patented ones. Branded generics can be very powerful growth engines for companies like Abbott."

In addition to targeting the key baby-boomer demographic, which is reaching the retirement age and is taking advantage of healthcare to live longer and healthier lives, Abbott offers investors exposure to emerging markets.

"You're seeing people consuming healthcare in order to improve the quality of their lives," Schoenstein says. "[Abbott has] been making acquisitions in countries like India, where they are acquiring branded generics that they can offer at a lower-price point to emerging market populations."
4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABT $36.50 -1.90%
MSFT $48.97 -1.50%
ORCL $34.81 -1.10%
PEP $96.61 -1.00%
TROW $64.80 -2.70%


Chart of I:DJI
DOW 15,560.85 -353.89 -2.22%
S&P 500 1,819.97 -31.89 -1.72%
NASDAQ 4,234.2370 -49.3550 -1.15%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs